XORTX Therapeutics Inc XRTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout
XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity
XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™
XORTX Announces Termination and Postponement of Investor Relations Program
Trading Information
- Previous Close Price
- $0.92
- Day Range
- $0.90–0.90
- 52-Week Range
- $0.86–3.60
- Bid/Ask
- $0.88 / $0.99
- Shares Outstanding
- 1.82M
- Market Cap
- $1.63M
- Volume/Avg
- 233 / 712,932
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 3
- Website
- https://www.xortx.com
Valuation
Metric | XRTX |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.29 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
XRTX
Financial Strength
Metric | XRTX |
|---|---|
Quick Ratio | 1.59 |
Current Ratio | 3.59 |
Interest Coverage | — |
Quick Ratio
XRTX
Profitability
Metric | XRTX |
|---|---|
Return on Assets (Normalized) | −117.19% |
Return on Equity (Normalized) | −274.16% |
Return on Invested Capital (Normalized) | −149.13% |
Return on Assets
XRTX
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|x!r>#jT | LOCK|c%#@ | $138B | |||
| Moderna Inc MRNA | LOCK|@<%pbdY | LOCK|k!$ | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|%!kW@?h | LOCK|zNF&T | $93B | |||
| argenx SE ADR ARGX | LOCK|&!&r>N@ | LOCK|$Hn | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|Yly?^# | LOCK|$l# | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|G!@<<F< | LOCK|fMjK | $30B | |||
| Incyte Corp INCY | LOCK|QpCl^l< | LOCK|@#V | $24B | |||
| BioNTech SE ADR BNTX | LOCK|>vNKxFV | LOCK|^X | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|X#l&JQm | LOCK|@?B< | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|c>w!Y#! | LOCK|!>k | $15B |
United States